Loading stock data…
NTRA
$199.14+4.90 (+2.52%)
After Hours$196.60-2.54 (-1.28%)· Last close May 11
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Natera, Inc. in the Healthcare sector is trading at $199.14. The stock is currently 22% below its 52-week high of $256.36, remaining 0.2% above its 200-day moving average. Technical signals show neutral RSI of 46 and bearish MACD signal, explaining why NTRA maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 46) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$199.14
Potential Upside
5%
Whystock Fair Value$209.10
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus18 analysts
Mean target$260.22+30.7%
Range$190.00 – $300.00
Fundamentals
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of tre...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$29.45B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.68
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-14.79%
Volume
Today's trading volume
1.95M
Recent News
Assessing Natera (NTRA) Valuation After Recent Share Price Pullback And Long Term Returns
Natera (NTRA) is back in focus after recent trading, with the stock closing at US$194.24 and showing mixed performance over the past week, month and past three months for investors tracking its moves. See our latest analysis for Natera. The recent 1 day share price drop of 11.64% has pulled Natera’s year to date share price return down 15.12%, although its 1 year total shareholder return of 23.49% and 3 year total shareholder return above 2x still signal strong longer term momentum. If...
Natera (NTRA) Is Up 6.6% After Record Q1 Revenue But Wider Losses - Has The Bull Case Changed?
In early May 2026, Natera, Inc. reported first‑quarter 2026 revenue of US$696.64 million versus US$501.83 million a year earlier, while net loss increased to US$85.09 million and basic and diluted loss per share from continuing operations widened to US$0.60 from US$0.50. Alongside record volumes of more than one million tests and stronger pricing that led management to raise full‑year revenue and gross margin guidance, the company’s wider loss highlighted the ongoing cost of funding clinical...
Natera Q1 Earnings Call Highlights
Natera (NASDAQ:NTRA) reported first-quarter 2026 revenue of $697 million, up 39% year over year, as the company delivered more than 1 million total units in a single quarter for the first time. Chief Executive Officer Steve Chapman said strong performance in women’s health and another record quarter
Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates
Natera (NTRA) delivered earnings and revenue surprises of -5.26% and +13.26%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Natera (NTRA) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.